Cell Robotics Reports 1997 Annual Results.

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--April 7, 1998--Cell Robotics International, Inc. (OTC:CRII) today announced its financial results for the year ending December 31, 1997.

The Company's 1997 revenues increased 57% to $1,037,723, compared to $663,261 in 1996. For the 1997 year end, the company reported a net loss for the year of $2,472,892 or ($.48) per share. This compared with a net loss of $1,544,090 or ($.37) per share 1996.

During 1997, Cell Robotics incurred large Research & Development costs as it transitioned the product line from being primarily laser research devices to a strong emphasis upon newly developed medical laser devices. The Research & Development costs are expected to decrease considerably in 1998.

The laser research device sales increased by 48%. This year the company has begun to sell the Lasette, an innovative laser-based medical device for sampling of capillary blood for subsequent glucose testing by diabetics. Sales of the In Vitro Fertilization Workstation have also begun.

In February 1998, the Company completed a Secondary Offering, which netted approximately $2.4 million in cash, which will provide the capital needed to launch the new medical products.

Cell Robotics International, Inc. develops, manufactures and markets several proprietary medical and research laser devices and associated products with application niches in large markets. Additional information is available on the Cell Robotics Web Site at http://www.cellrobotics.com/cell, by e-mail at [e-mail], or by telephone at [phone].

Note: Except for the historical information contained herein, the statements made in this release constitute forward-looking statements that involve certain risks and uncertainties. Certain factors may cause actual results to differ materially from those contained in the forward-looking statements; including the volume of sales of instruments by the Company and the ability of the Company to successfully manage its various contracts and the other factors detailed from time to time in the Company's reports on file with the Securities and Exchange Commission. -0-

                   CELL ROBOTICS INTERNATIONAL, INC.
                            AND SUBSIDIARY
                      Consolidated Balance Sheets
                      December 31, 1997 and 1996

                                               1997           1996
Assets
Current assets:
     Cash and cash equivalents           $    623,572    $  1,724,671
     Accounts receivable,
         net of allowance
         for doubtful accounts
         of $1,841 in
         1997 and 1996                        223,856          69,845
     Inventory                                586,033         408,173
     Other                                     36,089          19,121
              Total current assets          1,469,550       2,221,810

Property and equipment, net (note 3)          194,654         256,635

Deferred offering costs (note 10)             248,372            --

Other assets, net (note 4)                     67,271          92,507
                                         $  1,979,847    $  2,570,952
Liabilities and
Stockholders' Equity
Current liabilities:
     Accounts payable                    $    603,153    $    160,824
     Payroll related liabilities              149,726         128,932
     Royalties payable                        193,150          42,029
     Other current liabilities                 88,941          31,937
              Total current liabilities     1,034,970         363,722

Short-term loan refinanced subsequent to
     balance sheet date (note 10)             500,000            --
              Total liabilities             1,534,970         363,722

Stockholders' equity (notes 5 and 10):
     Preferred stock, $.04 par value
         Authorized 2,500,000
         shares, no shares
         issued and outstanding                  --              --
     Common stock, $.004 par value
         Authorized 12,500,000 shares,      5,245,414
         and 5,003,414 shares issued
         and outstanding
         in 1997 and 1996, respectively        20,982          20,014
     Additional paid-in capital            14,037,243      13,327,672
     Accumulated deficit                  (13,613,348)    (11,140,456)

          Total stockholders' equity          444,877       2,207,230

Commitments and
contingency (notes 6, 8 and 9)
                                         $  1,979,847    $  2,570,952


                   CELL ROBOTICS INTERNATIONAL, INC.
                            AND SUBSIDIARY
                 Consolidated Statements of Operations
            For the years ended December 31, 1997 and 1996


                                                1997           1996

Product sales                          $       879,490    $   594,071
Research and development grants                158,233         69,190
         Total revenues                      1,037,723        663,261

Product cost of goods sold                     599,153        427,341
SBIR direct expenses                           159,052         69,190
         Total cost of goods sold              758,205        496,531

Gross profit                                   279,518        166,730

Operating expenses:
     General and administrative                681,554        577,271
     Marketing                                 868,812        475,653
     Research and development                1,245,125        718,177
         Total operating expenses            2,795,491      1,771,101

Loss from operations                        (2,515,973)    (1,604,371)

Other income (deductions):
     Interest income                            32,004         40,645
     Interest expense                             (723)        (1,413)
     Other                                      11,800         21,049
         Total other income                     43,081         60,281

         Net loss                          $(2,472,892)   $(1,544,090)

Weighted average common shares
     outstanding, basic and diluted          5,100,032      4,197,499

Net loss per common share, basic
and diluted                               $      (.48)   $      (.37)


See accompanying notes to financial statements in the EDGAR File.

CONTACT: Newport Capital Consultants Inc.

Gary Bryant, 760/360-2326

or

Craig Rogers, VP for Investor Relations, 719/590-1793